This document provides an overview of the management of breast cancer. It discusses the epidemiology, risk factors, clinical features, diagnostic imaging, biopsy procedures, pathology, prognostic factors, and treatment options for breast cancer. Treatment may involve surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy, or a combination depending on the cancer type, stage, and patient characteristics. The goal of treatment is complete resection of the primary tumor and prevention of recurrence and metastasis to improve survival.
3. Introduction...
• Most frequently diagnosed life –
threatening cancer in women
• Leading cause of cancer death in
women
• A major public health issue globally
- 1 million new cases annually
- 400,000 annual death
- 4.4 million living with the dx
4. Epidemiology...
• Prevalence is worldwide
• Incidence is higher in the developed
world
• highest in North America,New
Zealand /Australia
• lowest in Asia & Sub- Sahara Africa
6. Risk factors...
Precise etiology is unknown
• Age : rises sharply with age,rare in <
25yrs
• Sex : 100x commoner in female
• Race/ethnicity : commoner in whites
• Family history : most widely recognized
breast cancer risk factors
5-10% of all breast
cancers are
hereditary
7. Risk factors...
Family history :
• One or more first degree relative with
breast or ovarian cancer
• Breast cancer occurring in an affected
relative < 50yrs
• Male relative with breast cancer
• BRCA1 and BRCA2 mutations
• Ataxia- telangiectasia heterozygotes
• Ashkenazi Jewish descent
8. -20 -30% women with BCA have atleast one
relative witness BCA
-Only 5- 10% of BCA patient have an identifiable
predisposed factor
-BRCA 1 & 2 account for 3- 8% of BCA & 15 &
20% of familiar cases.
9. Risk factors
·BRCA 1
-TSG located on xsome 17
-Life time risk of developing BCA & Ovarian CA
85% & 40%
-Mastectomy reduces the risk of BCA by 95%
10. Risk Factors
· BRCA 2
-Located on xsome 13
-Increase risk of male BCA
-Spectrum of associated BCA similar to non
carriers
11.
12. Risk factors....
Neoplastic conditions :
Previous breast cancer
Ovarian cancer
Endometrial Cancer
DCIS
LCIS
23. Imaging ...
• Ultrasonography
- further xterize a
mammographically detected
abnormality
- to identify a cystic mass
- alternative to mammography in
dense breast
- USS guided biopsy
- measure & clip a lesion prior to
neoadjuvant chemotherapy
- improved specificity when used
appropriately
24. • MRI
- Xterization of an indeterminate
lesion
- Detection of occult breast
cancer in px with carcinoma in an
axillary LN
- Evaluation of suspected
multifocal or bilateral tumor
25. Biopsy...
• A clinically suspicious mass should be
biopsized,irrespective of imaging findings
• FNAC
• Tissue Biopsy
• Open Biopsy
26. Other investigations...
• CXR
• FBC
• SERUM ALP
• LFT
• ABDOMINOPELVIC USS
• BONE SCAN
• HORMONE RECEPTOR STATUS
• HER2 OVEREXPRESSION
28. Molecular intrinsic subtypes...
• LUMINAL A
- ER +, &/or PR+, HER2 –
- Most common
- Less aggressive
- good prognosis
- Hormone responsible
- Increasing age
29. • LUMINAL B
- ER+, &/or PR+ ,HER2 +
- Worse prognosis than luminal A
• BASAL LIKE
- Triple Negative
- Aggressive subtype
- Younger ,pre-menopausal African
American
30. • HER2 +
- Less common
- Highly aggressive subtype
- young age
- African American
- Outcome improved with HER2
targeted therapy
37. Treatment ..
• Multimodality & Multidisciplinary
• Surgery is the primary treatment
modality-
early stage,cured with surgery alone
• Aim of surgery is complete resection
of the primary tumor with negative margins
& pathologic staging of the tumor & Axilla
40. DCIS
• Surgical resection + or – radiation
• ALND or SLNB not routinely
recommended
• Tamoxifen Only approved agent in px rx
with
BCS
• A precusor of invasive dx.
• Account for 5% of male breast cancer
41. LCIS
• Observation & close follow up care
with or without tamoxifen
• Bilateral mastectomy with or without
reconstruction
• Risk of invasive cancer is low(25-30%)
& equal in both breast.
42. Treatment- Early Breast Cancer(I
&II or T1-3,N0-1,M0)
• Loco – regional disease : surgery &/or
radiation therapy
• Systemic disease : one or combination
of chemotherapy,hormonal or biologic
therepy
46. Indications for Mastectomy
·Tumor size > 5cm
·Multicentric cancers
·Local recurrence ffg BCS
·Centrally located tumours
·No facillity for radiotherapy
47. INDICATIONS FOR
MASTECTOMY
*prior radiation therapy to the breast or chest wall
*Radiotherapy contraindicated In pregnancy
*Inflammatory breast cancer
*Persistent positive pathologic Margin
*Active connective tissue dx
48. Radiotherapy ...
• Routine in BCS,May be indicated post
mastectomy
• Aim is eradication of local residual
subclinical dx & minimize local recurrence
rates
• 2 approaches : EBRT or PBI
49. Post Mastectomy RT-
Indications
• Positive post mastectomy margins
• Primary tumors larger than 5cm
• Involvement of 4 or More LN
• Skin or Chest wall involvement
50. Side effects of RT...
• Fatigue
• Skin desquamation
• Breast pain
• Breast swelling
• Rib #
• Pulmonary fibrosis
• Cardiac dx
• Secondary malignancies
52. Indications for ALND
*Preoperative diagnosis of +ve ALND
*Prior Inadequate ALND
*+ve Intraoperative SLNB
*Failed Mapping of SLNB
*Clinically suspicious nodes at surgery
53. Axillary treatment...
• ALND or SLNB
• SLNB :Indicated in clinically node
Negative px
• Single modality for axillary treatment
56. Adjuvant systemic therapy...
• Aim is to prevent recurrence & improve
overall survival
• Choice of therapy depend on :
- hormone status
- menopausal status
- HER2 status
- risk of recurrence & potential
benefit
• Combination therapy
60. Neo adjuvant therapy..
• Aim is to improve surgical outcome &
surgical options
- operable BC,Increase the chances
of BCS
-Inoperable, LABC: Achieving
operability
61. LABC
• Locoregional Rx is based on tumor
response to neodjuvant
• Consist of surgery-either mastectomy
or BCS
& post operative RT
• surgery should be done ONLY if a
macroscopically complete resection is
possible
65. recurrence dx...
• Post BCS : Total mastectomy +
adjuvant chemotherapy or endocrine
therapy
• Post MRM : local resection of
recurrence where feasible + radiotherapy if
no RT b4.
66. Metastatic disease..
• Aim is to palliate symptoms,prolong
survival,maintain QOL
• Visceral metastasis- poor prognosis
• Chemotherapy is indicated for hrme
insensitive MBCA
• Hormone therapy preferred when ever
applicable
67. Conclusion...
• Breast cancer survival rates have
increased significantly, particularly in
younger women.
• The need for increased public
awareness & early detection cannot be
overemphasized.